Roivant Sciences Ltd. (ROIV) Stock Forecast & Price Target
Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 13, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Roivant Sciences Ltd. (ROIV), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Roivant Sciences Ltd., analysts forecast revenue rising from GBP 9.09M in 2026 to GBP 5.61B in 2031; the average estimate for 2031 earnings per share is GBP 2.86; with published estimates ranging from GBP 1.05 to GBP 4.66; 9 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (GBP)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast (GBP)
Roivant Sciences Ltd. (ROIV) forecast — frequently asked questions
What is the analyst price target for Roivant Sciences Ltd.?
Analysts covering Roivant Sciences Ltd. (ROIV) have a consensus price target of $47.71, 21.2% above the current price of $39.35. Published targets range from $41.00 to $55.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Roivant Sciences Ltd.'s earnings?
The average analyst estimate for Roivant Sciences Ltd. (ROIV) earnings per share in 2031 is 2.86, with individual estimates between 1.05 and 4.66.
How much revenue is Roivant Sciences Ltd. expected to make?
Analysts forecast Roivant Sciences Ltd. (ROIV) revenue of GBP 5.61B in 2031, based on 2 published estimates.
How many analysts cover ROIV?
9 analysts contribute estimates for Roivant Sciences Ltd. (ROIV). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.